Abstract |
Homoharringtonine is one of several Cephalotaxine esters which have shown experimental antineoplastic activity as well as anti- leukemia effects in patients in China. In a Phase I trial of homoharringtonine administered daily X 5 by bolus intravenous injection, the dose limiting toxicity was hypotension and the maximum tolerated dose was 3.5 mg/m2/d X 5. Evidence of drug induced cardiac irritability with resulting ventricular and atrial dysrhythmias was seen. Minimal myelosuppression was seen at this dose. Treatment of patients by 5 day continuous intravenous (rather than bolus) infusion resulted in more pronounced myelosuppression and clinically significant but tolerable hypotension. Significant reduction of white blood cell and platelet counts occurred at a dose of 3.5 mg/m2/day. Further investigations of the hypotensive and cardiac effects of homoharringtonine and Phase II trials using continuous infusion are indicated.
|
Authors | J A Stewart, I H Krakoff |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 3
Issue 3
Pg. 279-86
( 1985)
ISSN: 0167-6997 [Print] United States |
PMID | 4066221
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Alkaloids
- Antineoplastic Agents
- Harringtonines
- Homoharringtonine
|
Topics |
- Aged
- Alkaloids
(therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Drug Evaluation
- Female
- Harringtonines
(administration & dosage, adverse effects, therapeutic use)
- Heart
(drug effects)
- Homoharringtonine
- Humans
- Infusions, Parenteral
- Leukocyte Count
(drug effects)
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Platelet Count
(drug effects)
- Time Factors
|